BARING ASSET MANAGEMENT Ltd Increases Holdings in Eli Lilly and Company (LLY)

BARING ASSET MANAGEMENT Ltd raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 114.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,492 shares of the company’s stock after buying an additional 23,229 shares during the quarter. BARING ASSET MANAGEMENT Ltd’s holdings in Eli Lilly and were worth $3,721,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Airain ltd acquired a new stake in Eli Lilly and during the second quarter valued at approximately $567,000. Buckingham Asset Management LLC grew its holdings in shares of Eli Lilly and by 21.3% during the second quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock valued at $266,000 after purchasing an additional 568 shares during the last quarter. BSW Wealth Partners grew its holdings in shares of Eli Lilly and by 0.6% during the second quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock valued at $393,000 after purchasing an additional 27 shares during the last quarter. Sumitomo Life Insurance Co. grew its holdings in shares of Eli Lilly and by 4.4% during the second quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock valued at $2,675,000 after purchasing an additional 1,370 shares during the last quarter. Finally, Mirador Capital Partners LP grew its holdings in shares of Eli Lilly and by 5.3% during the second quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock valued at $1,011,000 after purchasing an additional 619 shares during the last quarter. Hedge funds and other institutional investors own 76.43% of the company’s stock.

Shares of Eli Lilly and Company (NYSE LLY) traded down $0.15 during mid-day trading on Friday, reaching $85.72. The company had a trading volume of 569,746 shares, compared to its average volume of 3,673,220. Eli Lilly and Company has a 1-year low of $66.39 and a 1-year high of $89.09. The company has a market cap of $93,945.43, a price-to-earnings ratio of 20.86, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The firm had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period last year, the company posted $0.88 EPS. sell-side analysts forecast that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.43%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s payout ratio is currently 98.58%.

Several research firms have recently commented on LLY. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, October 24th. Barclays upped their target price on Eli Lilly and from $90.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, October 13th. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a report on Thursday, October 26th. Zacks Investment Research lowered Eli Lilly and from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Cowen reissued a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a report on Wednesday, October 4th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. Eli Lilly and currently has an average rating of “Hold” and an average target price of $90.25.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 190,000 shares of the stock in a transaction on Friday, September 15th. The stock was sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the completion of the transaction, the insider now directly owns 123,682,287 shares of the company’s stock, valued at approximately $10,207,499,146.11. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Susan Mahony sold 36,585 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the transaction, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 628,588 shares of company stock valued at $53,399,536. 0.20% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “BARING ASSET MANAGEMENT Ltd Increases Holdings in Eli Lilly and Company (LLY)” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://ledgergazette.com/2017/12/08/baring-asset-management-ltd-increases-holdings-in-eli-lilly-and-company-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply